TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05731687

Intervention type: OTHER
Group type: OTHER
Intervention: Hybrid DEB approach with drug-eluting balloon
Description: If a patient is randomized to the hybrid DEB approach, lesion preparation of the SB with non-compliant balloon (NC) is mandatory before DEB application. The application of DEB can be performed if acceptable result of the lesion preparation is obtained (at least TIMI III flow and no flow limiting dissection). The drug- eluting balloon used in this study is the CE- marked Magic Touch Sirolimus Coated Balloon Catheter (Concept Medical, Gujarat, India). The size of the DEB is measured on a ratio 1:1 on reference diameter of the SB. The DEB balloon is inflated for 60 seconds, or two times more than 30 seconds if long duration inflations are not possible. Finally low pressure kissing inflation with the same DEB in place, and Proximal Optimization Therapy (POT) are performed. In case of SB occlusion, or flow limiting dissections in non-Left Main (LM) bifurcations and \< TIMI 3 flow or 70-99% residual stenosis in LM bifurcations, cross- over to two-stent technique is performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Two-stent strategy
Description: When randomized to the conventional two-stent strategy, TAP/T or Culotte stenting is performed. First lesion preparation of the SB is mandatory. The drug-eluting stent (Supraflex stent) can be placed in the SB if acceptable result of the lesion preparation is obtained and is measured on a 1:1 ratio on reference diameter of the SB. Finally, kissing inflation and POT are mandatory.
Study: NCT05826119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate group
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
Study: NCT06627127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target stimulation (HGN, AC, GG, Strap muscles)
Description: Stimulation of the HGN or GG along with AC or strap muscles.
Study: NCT05429463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Study: NCT06729632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold pack-delivered mild therapeutic hypothermia
Description: Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBoundRx.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold pack-delivered mild therapeutic hypothermia
Description: Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBoundRx.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold pack-delivered mild therapeutic hypothermia
Description: Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBoundRx.
Study: NCT06730919

Intervention type: DIAGNOSTIC_TEST
Intervention: Systemic autoimmune disease
Description: Preoperative diagnosis of pregnancy with systemic autoimmune diseases (systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis, Sjogren's syndrome, rheumatoid arthritis, undifferentiated connective tissue disease)
Study: NCT06742450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant current (CC) subthalamic nucleus deep brain stimulation
Description: For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant current (CC) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant current (CC) mode will be maintained.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant voltage (CV) subthalamic nucleus deep brain stimulation
Description: For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant voltage (CV) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant voltage (CV) mode will be maintained.
Study: NCT06741514

Intervention type: DEVICE
Intervention: Precice IMLL
Description: Parents or legal guardians of children that previously received the Precice IMLL will complete a survey. No additional or new interventions will be administered.
Study: NCT06741475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Assist Strategy Training
Description: CaST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing real-life limitations after stroke. During the intervention, the caregiver not only supervises the participant but also co-participates in the practice by instructing on when and how to be an assistant and facilitator when the stroke survivor executes their practice plan.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education
Description: Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequela, and adaptive skills for impaired functions are provided.
Study: NCT06742463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: BCL-2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: homoharringtonine
Description: alkaloid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara-C)
Description: Metabolic antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte colony-stimulating factor
Study: NCT06743113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemanext ONE System
Description: Hypoxic red blood cells

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional RBCs
Description: Conventional red blood cells
Study: NCT06741917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: single dose of oral Levofloxacin (500mg/tab) before retrograde intrarenal surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefmetazole (drug)
Description: single dose of intravenous Cefmetazole (1000 mg)before retrograde intrarenal surgery
Study: NCT06741553

Intervention type: DRUG
Intervention: Lecanemab 10 mg/kg
Description: Lecanemab was administered 10mg/kg every two weeks.
Study: NCT06743152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Synchronous exercise program
Description: The synchronous exercise group will be conducted online with synchronous supervision under the supervision of a physiotherapist. The exercise program will be performed for 8 weeks, 2 days a week. In the exercise program, 3 sets, 8 repetitions in 1 set will be progressed to 10-12-15-20-25 repetitions according to tolerance. There will be a 1-2 minute rest between sets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asynchronous exercise group
Description: The Asynchronous Exercise Group will be conducted with a video-based structured exercise program. For the asynchronous video-based group, a closed channel will be created on Youtube that only patients can access, and the exercises will be uploaded to the system asynchronously. In the asynchronous exercise group, how each exercise is performed will be shown in detail by the physiotherapist in the video content.
Study: NCT06741761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-hour time-restricted feeding (TRF12)
Description: The 12 hour feeding group will receive tube feeding only over a 12 hour period (6:00 AM to 6:00 PM feeding schedule).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous 24 hour feeding (CONT24).
Description: Patients in this control group will receive the standard of care which is tube feeding continuously over 24 hours.
Study: NCT06742658

Intervention type: OTHER
Intervention: Rapid Move
Description: A short-stay PACU where patients recover from anaesthesia, are continuously monitored, and prepared for discharge within an hour after surgery.
Study: NCT06743178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person injecting drugs
Description: Exposed to a photo of a person injecting drugs

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of EMS responding to an overdose (White)
Description: Exposed to a photo of EMS responding to an overdose (White)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of EMS responding to an overdose (Black)
Description: Exposed to a photo of EMS responding to an overdose (Black)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person receiving treatment (Jail)
Description: Exposed to a photo of a person receiving treatment (Jail)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person receiving treatment (Community)
Description: Exposed to a photo of a person receiving treatment (Community)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person in recovery (White)
Description: Exposed to a photo of a person in recovery (White)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a person in recovery (Black)
Description: Exposed to a photo of a person in recovery (Black)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo of a family member of an overdose decedent
Description: Exposed to a photo of a family member of an overdose decedent
Study: NCT05628311

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered subcutaneously (SC) once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: IBI362 administered subcutaneously (SC) once a week.
Study: NCT06113705

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-GE-180 PET
Description: PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Advanced MRI
Description: MRI examination using advanced sequences to characterize tumor microstructure and function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of hematopoietic stem cells
Description: Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of Cancer Stem Cells
Description: Glioblastoma stem cells (GSCs) will be isolated from the tumor
Study: NCT06075264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate ointment
Description: topical ointment, as a non-surgical treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: topical placebo ointment
Study: NCT05985564

Intervention type: OTHER
Intervention: imaging diagnosis
Description: no intervention
Study: NCT05764070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive auricular vagus stimulation
Description: The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non Invasive Vagus Stimulation
Description: Placebo Non Invasive Vagus Stimulation
Study: NCT06287567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lusutrombopag Oral Tablet
Description: Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and doses are adjusted based on platelet counts during week 5-12. If a subject's platelet count remains \< 50x10\^9 /L, the dose could have been increased up to a maximum dose of 6 mg（2 tablets).If a subject's platelet count reaches ≥ 250x10\^9 /L during the first 4 weeks, treatment is stopped and participants are allowed to enter into Titration Study in advance when platelet count drops to ≥100x10\^9 /L.
Study: NCT05340647

Intervention type: PROCEDURE
Intervention: Preserflo microshunt
Description: Implantation of Preserflo microshunt (Santen) to lower intraocular pressure

Intervention type: PROCEDURE
Intervention: Trabeculectomy
Description: Trabeculectomy surgery to lower intraocular pressure

Intervention type: PROCEDURE
Intervention: Other MIGS
Description: Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure
Study: NCT05572216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted partial nephrectomy with 3D image guidance
Description: patient have a partial nephrectomy for renal complex tumor
Study: NCT05662943

Intervention type: DRUG
Intervention: Intravitreal aflibercept injection
Description: Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)
Study: NCT04877639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmketamine,Dexmedetomidine
Description: Two different drugs were given to observe which of the two drugs was more suitable for DISE detection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmketamine,Dexmedetomidine
Description: Two different drugs were given to observe which of the two drugs was more suitable for DISE detection
Study: NCT05752331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavioural modification
Description: 8-week intervention consisting motivational interview, individualised action plan and weekly consultations regarding activities of daily living and symptom management.
Study: NCT05586100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab+cetuximab
Description: Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy.
Study: NCT05605080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelfoam
Description: Use Gelfoam as a hemostatic agent after anal surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bosmin gauze
Description: Use bosmin gauze as a hemostatic agent after anal surgery.
Study: NCT06254690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib dose escalation
Description: Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrotinib dose normal
Description: Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
Study: NCT06547801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2'-Fucosyllactose
Description: 3 g/day of powder orally once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 3 g/day of powder orally once daily
Study: NCT05291819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging informed treat-to-target
Description: A treat-to-target treatment strategy incorporating information from ultrasound assessment of joints, tendons and entheses (at every visit), and magnetic resonance imaging (MRI) of spine and sacroiliac (SI)-joints at baseline and 1 year, in addition to clinical information~Specifically, this means that these additional measures will be added to conventional treat to target:~* If evidence of enthesitis (power Doppler\>0 in enthesis) or axial inflammation (SPARCC score ≥ 2\* in SI-joint or SPARCC score ≥ 5 in presence of clinical symptoms of axial disease) on imaging the patient will progress directly to biological disease modifying antirheumatic drug in the treatment algorithm~* If evidence of ongoing inflammation (power Doppler\>0) on ultrasound assessment of joints, tendons or enthesis, the patient will be classified as not having reached their treatment target

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional treat-to-target
Description: Patients are treated according to an algorithm based on current European recommendations. The conventional treatment target, applicable to both arms and the target in the conventional arm, is all of: Disease Activity index in PSoriatic Arthritis (DAPSA) remission (≤4), Enthesitis ≤1, Psoriasis Body Surface Area ≤3%
Study: NCT06177457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as tablets; QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
Study: NCT04955470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Injectable Solution
Description: A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Injectable Solution
Description: A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9% Injectable Solution
Description: A 0.9% normal saline solution will be infused over a 40 minute period.